Injectable vaccine composition

Patent metadata

Field	Value
Publication number	US-9962439-B2
Application number	US-201414916807-A
Country	US
Kind code	B2
Filing date	Oct 2, 2014
Priority date	Oct 3, 2013
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia , Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter , Muricoccus, Neoasaia, Oleomonas , Paracraurococcus, Rhodopila , Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania , Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium , Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas , and Enterobacter , or a salt thereof.

First claim

The invention claimed is:

1. An injectable vaccine composition to be administered by injection to a human being or an animal, comprising:
at least one antigen, and
as an adjuvant, a lipopolysaccharide from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas , and Enterobacter , or a salt of the lipopolysaccharide;
wherein a mass ratio between the adjuvant and the antigen (total mass of the adjuvant/total mass of the antigen) is 0.002 to 50.

2. The injectable vaccine composition according to claim 1 , wherein the antigen is an infectious pathogen, an antigen from an infectious pathogen, or a cancer antigen.

Assignees

• Nitto Denko Corp

Inventors

• Matsushita Kyohei
• Fukasaka Masahiro
• Okazaki Arimichi
• KIYOTOH Eiji
• Okubo Katsuyuki
• Asari Daisuke
• Hori Mitsuhiko

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61K2039/55572

  Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title